GRAIL’s Methylation Assay Had 92% Cancer Detection Rate Across Six Hematologic Malignancies With 96% Accuracy in Determining the Hematologic Malignancy Subtype Findings Support Use of GRAIL’s Methylation Platform to Identify Residual Disease in Post-Treatment Settings MENLO PARK, Calif. & CAMBRIDGE, England–(BUSINESS WIRE)–GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it … [Read more…]

Covaris introduces an automatable, high-throughput deparaffinization and total nucleic acid extraction and purification workflow for FFPE samples WOBURN, Mass.–(BUSINESS WIRE)–Covaris, LLC, a leader in pre-analytical sample preparation technologies, proudly unveils a comprehensive, fully automatable deparaffinization and total nucleic acid extraction workflow for formalin-fixed paraffin-embedded (FFPE) samples. Covaris truXTRAC FFPE SMART Solutions are designed for use … [Read more…]

BEND, Ore.–(BUSINESS WIRE)–Inovia Vein Specialty Centers, a leading provider of vein disease treatments and therapies in the Pacific Northwest, announces its successful outreach and awareness efforts during DVT Awareness Month in March 2023. Throughout the month of March, the clinic dedicated its resources to raising awareness about the dangers of vein disease, as well as … [Read more…]

CAMARILLO, Calif.–(BUSINESS WIRE)–#biotechnology—Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, … [Read more…]

As researchers deepen their understanding of how sound waves affect the body, some propose using sound vibrations to relieve mental and emotional ailments HOT SPRINGS, Ariz.–(BUSINESS WIRE)–#IQubes–Between COVID-19 and a tumultuous political and social landscape, the mental health crisis in America has worsened like never before. In fact, the United States routinely spends 201 billion … [Read more…]

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & STAMFORD, Conn.–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1b trial of BeiGene’s RAF dimer inhibitor, lifirafenib, in combination with SpringWorks’ MEK inhibitor, mirdametinib, in patients with advanced … [Read more…]

BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. & SAN MATEO, Calif. & STAMFORD, Conn.–(BUSINESS WIRE)–MapKure, LLC, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), and SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), today announced that they will present updated clinical data from the Phase 1a/1b study of BGB-3245, an investigational, selective RAF dimer inhibitor, in adult patients … [Read more…]

Streamlining the provisioning of communications and collaboration solutions for the healthcare industry WALTHAM, Mass.–(BUSINESS WIRE)–#UCProvisioning–Mobile Heartbeat, the leading clinical communication and collaboration company, is pleased to announce a new partnership with Akkadian Labs, developer of the leading unified communications (UC) provisioning automation solution for enterprises and MSPs. Our flagship product, MH-CURE® now integrates with Akkadian … [Read more…]

PASADENA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today presented new preclinical data generated from engineered CD28 bispecific antibodies targeting the solid tumor antigens CEACAM5, ENPP3, mesothelin, STEAP1 and Trop-2. For each molecule, in vitro T cell activation was enhanced in … [Read more…]

BEIJING–(BUSINESS WIRE)–Avistone Biotechnology (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced interim results from its ongoing phase 1 study on PLB1004. The data were presented today (CT102) at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida USA. PLB1004, a novel mono-anilino-pyrimidine small molecule … [Read more…]